These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 19157107)

  • 21. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Garimella PS; Fink HA; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia].
    Song Y; Li NC; Wang XF; Ma LL; Wan B; Hong BF; Na YQ
    Zhonghua Nan Ke Xue; 2005 Sep; 11(9):674-6. PubMed ID: 16209208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Additional effect of propiverine for naftopidil-resistant nocturia in the patient with benign prostate hypertrophy].
    Kamimura N; Hatakeyama S; Kudo S; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Kawaguchi T; Takahashi S; Ohyama C
    Hinyokika Kiyo; 2011 Feb; 57(2):71-6. PubMed ID: 21412038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study.
    Masumori N; Tsukamoto T; Iwasawa A; Furuya R; Sonoda T; Mori M;
    Urol Int; 2009; 83(1):49-54. PubMed ID: 19641359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Silodosin and Naftopidil for Efficacy in the Treatment of Benign Prostatic Enlargement Complicated by Overactive Bladder: A Randomized, Prospective Study (SNIPER Study).
    Matsukawa Y; Funahashi Y; Takai S; Majima T; Ogawa T; Narita H; Kato M; Gotoh M
    J Urol; 2017 Feb; 197(2):452-458. PubMed ID: 27615436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia with overactive bladder].
    Kosugi S; Ikemoto I; Furuta A; Shimomura T; Kiyota H; Suzuki Y; Kishimoto K; Egaway S; Torii S; Shirai H; Takeuchi H; Abe K
    Nihon Hinyokika Gakkai Zasshi; 2007 Jul; 98(5):691-9. PubMed ID: 17682448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
    Takeda M; Nishizawa O; Gotoh M; Yoshida M; Takahashi S; Masumori N
    Urology; 2013 Oct; 82(4):887-93. PubMed ID: 23953605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cardura monotherapy versus combination therapy of cardura and tolterodine L-tartrate tablets for II° ? benign prostatic hyperplasia with overactive bladder].
    Wang YY; Shi GW; He JY; Zhang YB
    Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1099-102. PubMed ID: 24432622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Long-term efficacy of naftopidil for treatment of lower urinary tract symptoms with benign prostatic hyperplasia].
    Akasaka T; Funaki H; Hirano S; Ohinata M; Fujishima M; Kudou T; Suzuki A; Iinuma M
    Hinyokika Kiyo; 2003 Apr; 49(4):189-93. PubMed ID: 12784711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH].
    Xiao H; Li HZ; Yang Y; Huang ZM; Li YQ; Zhao XF
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(23):1590-3. PubMed ID: 17803845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The clinical efficacy and safety of naftopidil 75 mg on benign prostatic hyperplasia patients with moderate or severe urinary disturbance].
    Tsujihata M; Yoshimura K; Kojima Y; Oda M; Miyake O; Uchida K; Okuyama A
    Hinyokika Kiyo; 2009 Apr; 55(4):181-6. PubMed ID: 19462821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of supplemental administration of Eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with alpha1-adrenoceptor blocker].
    Naruoka T; Suzuki Y; Furuta A; Endo K; Sugaya S; Egawa S
    Hinyokika Kiyo; 2008 May; 54(5):341-4. PubMed ID: 18546857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study.
    Chung MS; Yoon BI; Lee SH
    Yonsei Med J; 2017 Jul; 58(4):800-806. PubMed ID: 28540994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of naftopidil on lower urinary tract symptoms after radical prostatectomy.
    Ishizaka K; Machida T; Tanaka M; Kawamura N; Nakamura K; Kihara K
    Int J Urol; 2009 Mar; 16(3):299-302. PubMed ID: 19207610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What Are Factors Contributing to Improvement of Overactive Bladder Symptoms after Alpha-1 Blocker Treatment in Patients with Both Storage and Voiding Symptoms?
    Matsukawa Y; Majima T; Takai S; Funahashi Y; Kato M; Gotoh M
    Urol Int; 2019; 103(4):439-443. PubMed ID: 31554005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study.
    Ukimura O; Kanazawa M; Fujihara A; Kamoi K; Okihara K; Miki T;
    Int J Urol; 2008 Dec; 15(12):1049-54. PubMed ID: 19120513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity].
    Gan W; Zhang SF; Jia HT; Xie S; Luo MH; Li YF
    Zhonghua Nan Ke Xue; 2011 Apr; 17(4):348-50. PubMed ID: 21548214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.